E
Revelation Biosciences, Inc.
REVB
$3.40
$0.061.80%
E
Sell
2/24/2025Downgrade
Revelation Biosciences, Inc. (REVB) was downgraded to E from E+ on 2/24/2025 due to a decline in the volatility index.
Revelation Biosciences, Inc. (REVB) was downgraded to E from E+ on 2/24/2025 due to a decline in the volatility index.
E
Sell
2/4/2025Upgraded
Revelation Biosciences, Inc. (REVB) was upgraded to E+ from E on 2/4/2025 due to a major increase in the growth index and volatility index.
Revelation Biosciences, Inc. (REVB) was upgraded to E+ from E on 2/4/2025 due to a major increase in the growth index and volatility index.
E
Sell
1/17/2025Downgrade
Revelation Biosciences, Inc. (REVB) was downgraded to E from E+ on 1/17/2025 due to a major decline in the growth index, solvency index and volatility index. Operating cash flow declined 273.46% from -$2.48M to -$9.26M.
Revelation Biosciences, Inc. (REVB) was downgraded to E from E+ on 1/17/2025 due to a major decline in the growth index, solvency index and volatility index. Operating cash flow declined 273.46% from -$2.48M to -$9.26M.
E
Sell
8/1/2024Upgraded
Revelation Biosciences, Inc. (REVB) was upgraded to E+ from E on 8/1/2024 due to an increase in the volatility index and total return index.
Revelation Biosciences, Inc. (REVB) was upgraded to E+ from E on 8/1/2024 due to an increase in the volatility index and total return index.
E
Sell
7/17/2024Downgrade
Revelation Biosciences, Inc. (REVB) was downgraded to E from E+ on 7/17/2024 due to a decline in the volatility index.
Revelation Biosciences, Inc. (REVB) was downgraded to E from E+ on 7/17/2024 due to a decline in the volatility index.
E
Sell
6/26/2024Upgraded
Revelation Biosciences, Inc. (REVB) was upgraded to E+ from E on 6/26/2024 due to an increase in the volatility index and total return index.
Revelation Biosciences, Inc. (REVB) was upgraded to E+ from E on 6/26/2024 due to an increase in the volatility index and total return index.
E
Sell
6/6/2024Downgrade
Revelation Biosciences, Inc. (REVB) was downgraded to E from E+ on 6/6/2024 due to a significant decline in the valuation index, volatility index and growth index. Operating cash flow declined 41.7% from -$2M to -$2.84M.
Revelation Biosciences, Inc. (REVB) was downgraded to E from E+ on 6/6/2024 due to a significant decline in the valuation index, volatility index and growth index. Operating cash flow declined 41.7% from -$2M to -$2.84M.
E
Sell
6/4/2024Upgraded
Revelation Biosciences, Inc. (REVB) was upgraded to E+ from E on 6/4/2024 due to an increase in the volatility index.
Revelation Biosciences, Inc. (REVB) was upgraded to E+ from E on 6/4/2024 due to an increase in the volatility index.
E
Sell
5/15/2024Downgrade
Revelation Biosciences, Inc. (REVB) was downgraded to E from E+ on 5/15/2024 due to a decline in the volatility index and total return index.
Revelation Biosciences, Inc. (REVB) was downgraded to E from E+ on 5/15/2024 due to a decline in the volatility index and total return index.
E
Sell
4/25/2024Upgraded
Revelation Biosciences, Inc. (REVB) was upgraded to E+ from E on 4/25/2024 due to an increase in the volatility index and solvency index.
Revelation Biosciences, Inc. (REVB) was upgraded to E+ from E on 4/25/2024 due to an increase in the volatility index and solvency index.
E
Sell
3/28/2024Downgrade
Revelation Biosciences, Inc. (REVB) was downgraded to E from E+ on 3/28/2024 due to a decline in the volatility index.
Revelation Biosciences, Inc. (REVB) was downgraded to E from E+ on 3/28/2024 due to a decline in the volatility index.
E
Sell
3/27/2024Downgrade
Revelation Biosciences, Inc. (REVB) was downgraded to E+ from D on 3/27/2024 due to a significant decline in the efficiency index and volatility index. Total capital declined 24.62% from $8.82M to $6.65M.
Revelation Biosciences, Inc. (REVB) was downgraded to E+ from D on 3/27/2024 due to a significant decline in the efficiency index and volatility index. Total capital declined 24.62% from $8.82M to $6.65M.
D
Sell
6/5/2023Upgraded
Revelation Biosciences, Inc. (REVB) was upgraded to D from E+ on 6/5/2023 due to a significant increase in the efficiency index, solvency index and growth index. Total capital increased 851.79% from $1.05M to $10.02M, net income increased 610.04% from -$1.21M to $6.16M, and earnings per share increased from -$1.6872 to $1.96.
Revelation Biosciences, Inc. (REVB) was upgraded to D from E+ on 6/5/2023 due to a significant increase in the efficiency index, solvency index and growth index. Total capital increased 851.79% from $1.05M to $10.02M, net income increased 610.04% from -$1.21M to $6.16M, and earnings per share increased from -$1.6872 to $1.96.
E
Sell
3/14/2023Downgrade
Revelation Biosciences, Inc. (REVB) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index.
Revelation Biosciences, Inc. (REVB) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index.
D
Sell
3/3/2023Upgraded
Revelation Biosciences, Inc. (REVB) was upgraded to D from D- on 3/3/2023 due to an increase in the volatility index.
Revelation Biosciences, Inc. (REVB) was upgraded to D from D- on 3/3/2023 due to an increase in the volatility index.
D
Sell
2/23/2023Upgraded
Revelation Biosciences, Inc. (REVB) was upgraded to D- from E+ on 2/23/2023 due to an increase in the volatility index and total return index.
Revelation Biosciences, Inc. (REVB) was upgraded to D- from E+ on 2/23/2023 due to an increase in the volatility index and total return index.
E
Sell
2/8/2023Downgrade
Revelation Biosciences, Inc. (REVB) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index and total return index.
Revelation Biosciences, Inc. (REVB) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index and total return index.
D
Sell
1/9/2023Downgrade
Revelation Biosciences, Inc. (REVB) was downgraded to D- from D on 1/9/2023 due to a decline in the volatility index.
Revelation Biosciences, Inc. (REVB) was downgraded to D- from D on 1/9/2023 due to a decline in the volatility index.
D
Sell
12/23/2022Upgraded
Revelation Biosciences, Inc. (REVB) was upgraded to D from D- on 12/23/2022 due to an increase in the volatility index.
Revelation Biosciences, Inc. (REVB) was upgraded to D from D- on 12/23/2022 due to an increase in the volatility index.
D
Sell
12/8/2022Downgrade
Revelation Biosciences, Inc. (REVB) was downgraded to D- from D on 12/8/2022 due to a decline in the volatility index.
Revelation Biosciences, Inc. (REVB) was downgraded to D- from D on 12/8/2022 due to a decline in the volatility index.
D
Sell
11/17/2022Upgraded
Revelation Biosciences, Inc. (REVB) was upgraded to D from D- on 11/17/2022 due to a large increase in the growth index, solvency index and total return index. The quick ratio increased from 0.58 to 1.42, earnings per share increased from -$0.1216 to -$0.0556, and operating cash flow increased 53.34% from -$3.71M to -$1.73M.
Revelation Biosciences, Inc. (REVB) was upgraded to D from D- on 11/17/2022 due to a large increase in the growth index, solvency index and total return index. The quick ratio increased from 0.58 to 1.42, earnings per share increased from -$0.1216 to -$0.0556, and operating cash flow increased 53.34% from -$3.71M to -$1.73M.
D
Sell
8/18/2022Upgraded
Revelation Biosciences, Inc. (REVB) was upgraded to D- from E+ on 8/18/2022 due to an increase in the volatility index and total return index.
Revelation Biosciences, Inc. (REVB) was upgraded to D- from E+ on 8/18/2022 due to an increase in the volatility index and total return index.
E
Sell
8/2/2022Downgrade
Revelation Biosciences, Inc. (REVB) was downgraded to E+ from D- on 8/2/2022 due to a decline in the volatility index.
Revelation Biosciences, Inc. (REVB) was downgraded to E+ from D- on 8/2/2022 due to a decline in the volatility index.
D
Sell
7/13/2022Upgraded
Revelation Biosciences, Inc. (REVB) was upgraded to D- from E+ on 7/13/2022 due to an increase in the volatility index and total return index.
Revelation Biosciences, Inc. (REVB) was upgraded to D- from E+ on 7/13/2022 due to an increase in the volatility index and total return index.
E
Sell
6/27/2022Downgrade
Revelation Biosciences, Inc. (REVB) was downgraded to E+ from D- on 6/27/2022 due to a decline in the volatility index.
Revelation Biosciences, Inc. (REVB) was downgraded to E+ from D- on 6/27/2022 due to a decline in the volatility index.
D
Sell
6/8/2022Upgraded
Revelation Biosciences, Inc. (REVB) was upgraded to D- from E+ on 6/8/2022 due to a noticeable increase in the growth index, solvency index and volatility index.
Revelation Biosciences, Inc. (REVB) was upgraded to D- from E+ on 6/8/2022 due to a noticeable increase in the growth index, solvency index and volatility index.
E
Sell
5/24/2022Downgrade
Revelation Biosciences, Inc. (REVB) was downgraded to E+ from D on 5/24/2022 due to a major decline in the efficiency index, growth index and volatility index. EBIT declined 231.59% from $5.01M to -$6.59M, net income declined 210.35% from $6M to -$6.62M, and operating cash flow declined 164.52% from $7.49M to -$4.83M.
Revelation Biosciences, Inc. (REVB) was downgraded to E+ from D on 5/24/2022 due to a major decline in the efficiency index, growth index and volatility index. EBIT declined 231.59% from $5.01M to -$6.59M, net income declined 210.35% from $6M to -$6.62M, and operating cash flow declined 164.52% from $7.49M to -$4.83M.
D
Sell
4/19/2022None
Revelation Biosciences, Inc. (REVB) was downgraded to D from U on 04/19/2022.
Revelation Biosciences, Inc. (REVB) was downgraded to D from U on 04/19/2022.
NASDAQ
03/12/2025 4:00PM Eastern
Quotes delayed
